GlaxoSmithKline, which is cutting back mostly neither in detailing nor in sampling, failed to disclose safety data about Avandia, Wellbutrin, and Paxil, thus allegedly violating the False Claims Act, which they settled with $3 billion.
The charges stemmed from GSK's promotion of the anti-depressants Paxil (paroxetine) and Wellbutrin (bupropion) for unapproved uses from 1998 to 2003, specifically as suitable for patients under the age of 18, and from its failure to report safety data about Avandia (rosiglitazone), both in violation of the Federal Food, Drug, and Cosmetic Act. The investigation was launched largely on the basis of information from four whistleblowers who filed qui tam (whistleblower) lawsuits against the company under the False Claims Act. In 2012, GSK pleaded guilty to promotion of drugs for unapproved uses, failure to report safety data, and kickbacks to physicians in the United States and agreed to pay a US$3 billion (1.9bn) settlement. 
